Immunotherapeutics for Tuberculosis in Experimental Animals: Is There a Common Pathway Activated by Effective Protocols?

• Published in: The Journal of infectious diseases Vol. 196; no. 2; pp. 191 - 198
• Main Authors: Rook, Graham A. W., Lowrie, Douglas B., Hernández-Pando, Rogelio
• Format: Journal Article
• Language: English
• Published: Chicago, IL The University of Chicago Press 15-07-2007; University of Chicago Press
• Subjects: Animals; Bacterial diseases; Biological and medical sciences; CD8-Positive T-Lymphocytes - immunology; Disease Models, Animal; Human bacterial diseases; Humans; Immunotherapy; Immunotherapy, Active - methods; Infections; Infectious diseases; Interleukin-4 - immunology; Interleukin-4 - metabolism; Medical sciences; Medical treatment; Mice; Mycobacterium; Mycobacterium tuberculosis; Perspectives; Pulmonary tuberculosis; T lymphocytes; Transforming Growth Factor beta - immunology; Transforming Growth Factor beta - metabolism; Tuberculosis; Tuberculosis - immunology; Tuberculosis - therapy; Tuberculosis and atypical mycobacterial infections; Tuberculosis vaccine; Tuberculosis Vaccines - pharmacology; Vaccination; Infection; Bacteriosis; Tuberculosis; Mycobacterial infection
• ISSN: 0022-1899; 1537-6613
• DOI: 10.1086/518937

The increasing threat posed by drug-resistant strains of M. tuberculosis is leading to a reappraisal of the possibility of treating tuberculosis (TB) by immunotherapy. We analyze 6 strategies that have been shown to be therapeutic in animal models of TB and identify a common pathway underlying the activity of the superficially different immunotherapeutic protocols. This pathway involves enhanced induction of CD8+ cytotoxic T lymphocytes (CTLs), and down-regulation of interleukin-4 and transforming growth factor–β, leading to further enhancement of the activity of CD8+ CTLs and of other microbicidal pathways. This unifying analysis strengthens the rationale for future trials of immunotherapy in humans and points to surrogate markers that could be studied in such trials.